HonorHealth Research Institute - Biltmore ( Site 8009) — Phoenix, Arizona

HonorHealth Research Institute - Biltmore ( Site 8009) is a clinical research site located in Phoenix, Arizona, United States 85016.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

HonorHealth Research Institute - Biltmore ( Site 8009) has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Uterine Cervical Neoplasms, Endometrial Neoplasms.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Phoenix

Browse all research sites in Arizona · View every site in Phoenix

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for HonorHealth Research Institute - Biltmore ( Site 8009)?

HonorHealth Research Institute - Biltmore ( Site 8009) has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has HonorHealth Research Institute - Biltmore ( Site 8009) conducted?

HonorHealth Research Institute - Biltmore ( Site 8009) has 2 clinical trials on record, with 1 currently active. Their work covers Uterine Cervical Neoplasms, Endometrial Neoplasms.

Is HonorHealth Research Institute - Biltmore ( Site 8009) accredited by Crixeo Clinical Trials?

HonorHealth Research Institute - Biltmore ( Site 8009) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about HonorHealth Research Institute - Biltmore ( Site 8009)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.